Astal Laboratories Limited has filed its quarterly Statement of Deviation and Variation with BSE Limited for the quarter ended 31st December 2025, as required under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The statement was reviewed and approved by the company's Audit Committee and Board of Directors in their meeting held on 14th February 2026.

Fund Raising Details

The company, formerly known as Macro International Limited, raised funds through preferential allotment during the current financial year. The fund raising exercise was completed on 12th August 2025, generating proceeds of Rs. 281.98 lakhs for the company.

Fund Utilization Status

According to the regulatory filing, the company has utilized Rs. 218.10 lakhs out of the total Rs. 281.98 lakhs raised. The funds were deployed for their originally stated objectives without any deviation from the approved purposes.

The original object for fund raising was to meet the long-term funding requirements of the company for capital expenditure, working capital, and general corporate purposes. The company confirmed that there has been no modification to these original objectives.

Regulatory Compliance

The statement confirms that there is no deviation or variation in the use of funds raised from their originally disclosed purposes. Both the Audit Committee and the company's auditors have provided "No Comments" on the fund utilization, indicating compliance with the stated objectives.

The filing was signed by Mahendra Kumar, Company Secretary and Compliance Officer (Membership No. A71224), and submitted from the company's corporate office in Hyderabad. The company operates under CIN L74120UP1993PLC015605 and is listed on BSE with scrip code 512600.

Astal Laboratories Limited has announced a substantial equity investment through the allotment of 29,56,666 shares to non-promoter investors under a preferential allotment arrangement. The transaction, completed on January 14, 2026, represents a significant capital infusion for the pharmaceutical company.

Share Allotment Details

The preferential allotment was made to two non-promoter investors through a share swap mechanism. The distribution of shares and their impact on shareholding is detailed below:

Both investors previously held zero shares in the company, making this their initial investment in Astal Laboratories. The allotment was made pursuant to SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Capital Structure Transformation

The preferential allotment has significantly altered the company's capital structure. The equity share capital witnessed substantial growth following this transaction:

The transaction represents an investment of approximately ₹29.57 crores based on the face value of ₹10 per share, demonstrating significant investor confidence in the company's prospects.

Regulatory Compliance

Astal Laboratories has fulfilled all regulatory requirements under SEBI regulations. The company submitted the necessary disclosures to BSE Limited on January 19, 2026, through Company Secretary Mahendra Kumar. The disclosure was made in the prescribed format under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

The share swap arrangement facilitated this preferential allotment, indicating a strategic transaction rather than a cash-based investment. This method of capital raising suggests potential synergies or strategic partnerships between the parties involved.

Company Profile

Astal Laboratories Limited, formerly known as Macro International Limited, operates from its registered office in Noida, Uttar Pradesh, with corporate offices in Telangana. The company trades on BSE Limited under scrip code 512600 with the security ID ASTALLTD. The pharmaceutical company has been incorporated since 1993 and maintains its focus on laboratory and pharmaceutical operations.